Brian R. Mueller
Net Worth

Last updated:

What is Brian R. Mueller net worth?

The estimated net worth of Mr. Brian R. Mueller is at least $27,996,783 as of 30 May 2024. He owns shares worth $4,113,063 as insider, has earned $10,086,580 from insider trading and has received compensation worth at least $13,797,140 in BioMarin Pharmaceutical Inc..

What is the salary of Brian R. Mueller?

Mr. Brian R. Mueller salary is $985,510 per year as Executive Vice President of Fin. & Chief Financial Officer in BioMarin Pharmaceutical Inc..

How old is Brian R. Mueller?

Mr. Brian R. Mueller is 51 years old, born in 1974.

What stocks does Brian R. Mueller currently own?

As insider, Mr. Brian R. Mueller owns shares in one company:

Company Title Shares Price per share Total value
BioMarin Pharmaceutical Inc. (BMRN) Executive Vice President of Fin. & Chief Financial Officer 72,159 $57 $4,113,063

What does BioMarin Pharmaceutical Inc. do?

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN logo
BMRN
BioMarin Pharmaceutical Inc.
$57

Brian R. Mueller insider trading

BioMarin Pharmaceutical Inc.

Mr. Brian R. Mueller has made 34 insider trades between 2011-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 16,758 units of BMRN stock on 8 May 2012. As of 30 May 2024 he still owns at least 72,159 units of BMRN stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 5,000 $63.1 $315,500
Option
Stock Option (Right to Buy Common Stock) 5,000 $63.1 $315,500
Sale
Common Stock 5,000 $75.19 $375,950
Option
Stock Option (Right to buy Common Stock) 2,500 $63.1 $157,750
Option
Common Stock 2,500 $63.1 $157,750
Sale
Common Stock 2,500 $114.5 $286,250
Sale
Common Stock 2,500 $107.5 $268,750
Option
Stock Option (Right to buy Common Stock) 2,500 $63.1 $157,750
Option
Common Stock 2,500 $63.1 $157,750
Option
Stock Option (Right to buy Common Stock) 3,761 $67.81 $255,033
Sale
Common Stock 3,761 $104.5 $393,025
Option
Common Stock 2,139 $67.81 $145,046
Option
Common Stock 3,761 $67.81 $255,033
Option
Stock Option (Right to buy Common Stock) 3,500 $67.81 $237,335
Sale
Common Stock 934 $95.09 $88,814
Sale
Common Stock 3,500 $99.5 $348,250
Option
Common Stock 3,500 $67.81 $237,335
Option
Stock Option (Right to buy Common Stock) 3,500 $67.81 $237,335
Option
Common Stock 3,500 $67.81 $237,335
Sale
Common Stock 3,500 $94.5 $330,750
Sale
Common Stock 7,337 $89.5 $656,662
Option
Common Stock 2,038 $37.46 $76,343
Option
Stock Option (Right to buy Common Stock) 9,762 $37.46 $365,685
Option
Common Stock 9,762 $37.46 $365,685
Sale
Common Stock 9,762 $84.5 $824,889
Sale
Common Stock 6,709 $28.23 $189,395
Option
Common Stock 6,709 $28.23 $189,395
Option
Stock Option (Right to buy Common Stock) 6,709 $28.23 $189,395
Sale
Common Stock 5,692 N/A N/A
Sale
Common Stock 2,953 $94 $277,582
Sale
Common Stock 2,500 $104.5 $261,250
Option
Common Stock 2,500 $28.23 $70,575
Option
Stock Option (Right to buy Common Stock) 2,500 $28.23 $70,575
Option
Stock Option (Right to buy Common Stock) 2,491 $28.23 $70,321
Sale
Common Stock 654 $99.5 $65,073
Option
Common Stock 2,491 $28.23 $70,321
Sale
Common Stock 2,021 $94.5 $190,985
Sale
Common Stock 2,450 $89.5 $219,275
Option
Stock Option (Right to buy Common Stock) 2,671 $21.51 $57,453
Option
Common Stock 2,671 $21.51 $57,453
Sale
Common Stock 2,671 $21.51 $57,453
Option
Common Stock 2,600 $21.51 $55,926
Option
Stock Option (Right to buy Common Stock) 2,600 $21.51 $55,926
Sale
Common Stock 4,882 $91.17 $445,092
Sale
Common Stock 287 $100 $28,700
Sale
Common Stock 7,000 $28.23 $197,610
Option
Common Stock 7,000 $28.23 $197,610
Option
Stock Option (right to buy Common Stock) 12,000 $60.03 $720,300
Option
Common Stock 5,000 $91.82 $459,100
Sale
Common Stock 5,000 $91.82 $459,100
Option
Stock Option (right to buy Common Stock) 521 $14.39 $7,497
Sale
Common Stock 6,950 $90.25 $627,238
Option
Common Stock 6,950 $17.95 $124,753
Sale
Common Stock 3,400 $88.97 $302,508
Option
Common Stock 3,500 $21.51 $75,285
Option
Common Stock 3,500 $21.51 $75,285
Sale
Common Stock 1,447 $70.42 $101,891
Option
Stock Option (right to buy) Common Stock 4,874 $65.35 $318,496
Option
Common Stock 7,500 $21.51 $161,325
Sale
Common Stock 7,500 $21.51 $161,325
Option
Stock Option (right to buy) Common Stock 7,500 $21.51 $161,325
Sale
Common Stock 9,331 $65.42 $610,387
Option
Common Stock 4,874 $65.35 $318,496
Sale
Common Stock 2,015 $59.81 $120,511
Option
Stock Option (right to buy) Common Stock 5,023 $23.61 $118,608
Option
Common Stock 5,023 $23.61 $118,608
Sale
Common Stock 5,023 $59.74 $300,069
Option
Common Stock 15,812 $26.49 $418,860
Sale
Common Stock 15,812 $50 $790,600
Option
Stock Option (right to buy) Common Stock 15,812 $26.49 $418,860
Option
Common Stock 8,000 $14.39 $115,120
Option
Stock Option (right to buy) Common Stock 8,000 $14.39 $115,120
Sale
Common Stock 8,000 $46.75 $374,000
Purchase
Common Stock 548 $21.76 $11,924
Option
Stock Option (right to buy) Common Stock 2,500 $14.39 $35,975
Sale
Common Stock 2,500 $14.39 $35,975
Option
Common Stock 2,500 $14.39 $35,975
Option
Stock Option (right to buy) Common Stock 2,770 $17.86 $49,472
Option
Common Stock 2,770 $17.86 $49,472
Sale
Common Stock 2,770 $17.86 $49,472
Option
Restricted Stock Units 150 N/A N/A
Option
Common Stock 150 N/A N/A
Option
Common Stock 1,562 N/A N/A
Option
Restricted Stock Units 1,562 N/A N/A
Sale
Common Stock 15,708 $37.5 $589,050
Option
Common Stock 15,708 $16.48 $258,836
Option
Stock Option (right to buy) 16,758 $14.33 $240,075
Option
Stock Option (right to buy) 5,000 $11.74 $58,700
Sale
Common Stock 5,000 $11.74 $58,700
Option
Common Stock 5,000 $11.74 $58,700
Purchase
Common Stock 964 $13.23 $12,750
Option
Common Stock 1,562 N/A N/A
Option
Restricted Stock Units 1,562 N/A N/A

BioMarin Pharmaceutical key executives

BioMarin Pharmaceutical Inc. executives and other stock owners filed with the SEC:

  • Dr. C. Greg Guyer Ph.D. (63) Chief Technology Officer and Executive Vice President of Global Manufacturing & Technical Operations
  • Dr. Henry J. Fuchs (67) Pres of Worldwide R&D
  • Mr. Brian R. Mueller (51) Executive Vice President of Fin. & Chief Financial Officer
  • Mr. Jean-Jacques Bienaime M.B.A., MBA (72) Chairman & Chief Executive Officer
  • Mr. Jeffrey Robert Ajer (63) Executive Vice President & Chief Commercial Officer